WRAPSODY動脈静脈アクセス効率 (WAVE) 試験のランダム化制御アームからの1年間の臨床結果
Mahmood K Razavi1, Saravanan Balamuthusamy2, Angelo N Makris3
1St. Joseph Heart and Vascular Center, Orange, California, USA.
Journal of vascular and interventional radiology : JVIR
|February 18, 2026
まとめ
WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) は,皮膚経膜血管形成術 (PTA) と比較して,血液透析患者における血管アクセス通路性を著しく改善しました. CIE治療は,より高い開通率と,12ヶ月後に再介入の少ない結果をもたらしました.
科学分野:
- 血管外科 血管外科
- ネフロロジーはネフロロジーを用います.
- 介入放射線学とは,介入放射線学です.
背景:
- 血管アクセス狭窄症は,血液透析患者の一般的な合併症であり,アクセス障害と罹病率の増加につながる.
- 十分な動脈静脈胞 (AVF) の透かし性を維持することは,効果的な血液透析治療に不可欠です.
研究 の 目的:
- WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) の12ヶ月の有効性および安全性評価を,AVF狭窄の患者における皮膚経膜血管形成 (PTA) と比較して評価する.
- WAVE試験のランダム化制御アームで,ターゲット病変のプライマリパテンシー (TLPP) とアクセス回路のプライマリパテンシー (ACPP) を評価する.
主な方法:
- 展望型,多センター,ランダム化対照試験 (WAVE試験) で,AVF狭窄の血液透析患者245人が参加した.
- 患者は1対1でランダムにWRAPSODY® CIEまたはPTAのいずれかの治療に割り当てられました.
- 12ヶ月で測定された主なアウトカムには,TLPP,ACPP,再介入率,デバイス関連のイベント,重篤な有害事象が含まれています.
主要な成果:
- WRAPSODY® CIEは,PTAと比較して12ヶ月で,TLPP (69.4%対38.5%,p<0.0001) とACPP (56.4%対31.1%,p=0.0002) が著しく高いことを示した.
- CIEで治療された患者は,標的病変 (0.50対1.08,p<0.0001) とアクセス回路の穿透性 (1.08対1.70,p=0.001) の両方で,再介入を大幅に少なくする必要がありました.
- デバイス関連のイベントはCIEではより低かった (2.9%対9.5%,p=0.049),重篤な有害事象では有意な違いはなかった.
結論:
- WRAPSODY® CIEは,静脈流出回路狭窄症の血液透析患者に対する血管アクセス通路の延長に優れた性能を提供します.
- これらの発見は,AVFの狭窄を管理する臨床医にとって貴重な証拠を提供し,長期的なアクセス結果を改善するためにCIEの使用を支持します.
関連する概念動画
Peripheral Artery Disease V: Postoperative Nursing Management
431
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
431
Peripheral Artery Disease IV: Nursing Management
405
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
405
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
472
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
472
Hemodialysis II: Procedure and Complications
1.1K
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
1.1K
Hemodialysis I: Introduction
2.0K
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
2.0K


